Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedUpdated Publications section wording to clarify that publications are provided by the submitting party and pertain to study results. Added template revision indicator Revision: v3.3.2.SummaryDifference0.1%

- Check23 days agoChange DetectedRemoval of the government funding/operating status notice from the page; it does not affect trial details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check38 days agoChange DetectedCore study information such as design, eligibility criteria, primary/secondary outcomes, and locations appears unchanged; only formatting and non-substantive details seem updated. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check66 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check73 days agoChange Detected- Version indicator updated from v3.0.2 to v3.1.0, signaling a new release.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.